LFST (LifeStance Health Group, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by LFST officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-04 | David Bourdon | Chief Executive Officer | J | — | — |
| 2026-09-04 | Vukasin Paunovich | Chief Technology Officer | Sell | — | — |
| 2026-08-26 | Ann Varanakis | Chief People Officer | F | — | — |
| 2026-08-18 | Teresa DeLuca | Director | Sell | — | — |
| 2026-08-14 | Teresa DeLuca | Director | Sell | — | — |
| 2026-08-13 | Kenneth A Burdick | Director | Sell | — | — |
| 2026-08-12 | Lisa K Miller | Chief Operating Officer | Sell | — | — |
| 2026-08-12 | Vukasin Paunovich | Chief Technology Officer | Sell | — | — |
| 2026-08-12 | JAMES G COULTER | 10%+ Owner | Sell | — | — |
| 2026-07-14 | Kenneth A Burdick | Director | A | — | — |
| 2026-07-07 | Sarah Personette | Director | A | — | — |
| 2026-07-07 | Teresa DeLuca | Director | A | — | — |
| 2026-07-07 | Thurman Justice | Director | A | — | — |
| 2026-07-07 | Lori Goltermann | Director | A | — | — |
| 2026-07-07 | Eric P Palmer | Director | A | — | — |
| 2026-07-07 | Robert Bessler | Director | A | — | — |
| 2026-06-15 | Vukasin Paunovich | Chief Technology Officer | F | — | — |
| 2026-05-14 | DARREN M. BLACK | Director | Sell | — | — |
| 2026-05-14 | Eric Shuey | Director | Sell | — | — |
| 2026-05-14 | Robert Bessler | Director | Sell | — | — |
| 2026-05-14 | JAMES G COULTER | 10%+ Owner | Sell | — | — |
| 2026-05-11 | Robert Bessler | Director | Sell | — | — |
| 2026-04-27 | Robert Bessler | Director | Sell | — | — |
| 2026-04-23 | Robert Bessler | Director | Sell | — | — |
| 2026-04-03 | Ryan Pardo | See Remarks | F | — | — |
| 2026-03-26 | Ryan McGroarty | See Remarks | F | — | — |
| 2026-03-19 | Ryan McGroarty | See Remarks | F | — | — |
| 2026-03-11 | Lisa K Miller | Chief Operating Officer | MIXED | — | — |
| 2026-03-11 | Kenneth A Burdick | Director | MIXED | — | — |
| 2026-03-11 | David Bourdon | Chief Executive Officer | MIXED | — | — |
| 2026-03-11 | Vukasin Paunovich | Chief Technology Officer | MIXED | — | — |
| 2026-03-11 | Ryan McGroarty | See Remarks | MIXED | — | — |
| 2026-03-11 | Ryan Pardo | See Remarks | MIXED | — | — |
| 2026-03-11 | Ann Varanakis | Chief People Officer | MIXED | — | — |
| 2026-03-09 | Stephanie Carin Eken | Chief Medical Officer | A | — | — |
| 2026-03-09 | Ann Varanakis | Chief People Officer | MIXED | — | — |
| 2026-03-09 | David Bourdon | Chief Executive Officer | MIXED | — | — |
| 2026-03-09 | Ryan McGroarty | See Remarks | A | — | — |
| 2026-03-09 | Ryan Pardo | See Remarks | MIXED | — | — |
| 2026-03-09 | Lisa K Miller | See Remarks | MIXED | — | — |
| 2026-03-09 | Kenneth A Burdick | Director | F | — | — |
| 2026-03-09 | Vukasin Paunovich | Chief Technology Officer | A | — | — |
| 2026-03-04 | DARREN M. BLACK | Director | Sell | — | — |
| 2026-03-04 | JON WINKELRIED | 10%+ Owner | Sell | — | — |
| 2025-12-23 | Robert Bessler | Director | Sell | — | — |
| 2025-12-19 | Ann Varanakis | Chief People Officer | Sell | — | — |
| 2025-12-19 | Robert Bessler | Director | Sell | — | — |
| 2025-12-16 | Robert Bessler | Director | Sell | — | — |
| 2025-11-25 | Lisa K Miller | See Remarks | Sell | — | — |
| 2025-11-13 | Lisa K Miller | See Remarks | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 160,711,618 | — |
| — | 10%+ Owner | 140,026,557 | — |
| — | 10%+ Owner | 98,101,407 | — |
| — | 10%+ Owner | 46,875,407 | — |
| — | — | 46,875,407 | — |
| — | — | 45,734,703 | — |
| — | — | 41,932,358 | — |
| — | 10%+ Owner | 41,932,358 | — |
| — | — | 33,524,715 | — |
| — | Director | 23,310,115 | — |
| — | President and CEO | 23,148,931 | — |
| — | — | 17,916,554 | — |
| — | Director | 17,916,554 | — |
| — | 10%+ Owner | 14,324,197 | — |
| — | Chief Operating Officer | 7,083,637 | — |
| — | Chief Administrative Officer | 5,996,104 | — |
| — | See Remarks | 5,416,943 | — |
| — | Chief Development Officer | 4,650,571 | — |
| — | See Remarks | 3,644,886 | — |
| — | Director | 3,017,321 | — |
| — | Chief Medical Officer | 2,371,505 | — |
| — | Chief Financial Officer | 1,928,369 | — |
| — | Chief Digital Officer | 1,437,881 | — |
| — | Chief Executive Officer | 1,248,247 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LFST quote page; the site-wide leaderboard is on the insider transactions hub.